Population Pharmacokinetics and Exposure–Response (Efficacy and Safety/Tolerability) of Empagliflozin in Patients with Type 2 Diabetes
Crossref DOI link: https://doi.org/10.1007/s13300-016-0174-y
Published Online: 2016-06-16
Published Print: 2016-09
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Baron, Kyle T.
Macha, Sreeraj
Broedl, Uli C.
Nock, Valerie
Retlich, Silke
Riggs, Matthew
Text and Data Mining valid from 2016-06-16
Article History
Received: 15 February 2016
First Online: 16 June 2016